| Business Summary | | BEI
Medical
Systems
Company,
Inc.
is
focusing
on
developing
and
commercializing
a
new
therapeutic
system,
the
Hydro
ThermAblator
(the
HTA),
for
treatment
of
menorrhagia
or
dysfunctional
uterine
bleeding.
Approval
to
market
this
system
in
the
United
States
is
dependent
upon
authorization
from
the
United
States
Food
and
Drug
Administration
(FDA).
The
Company
completed
12-month,
post-treatment
follow-up
examinations
in
August
2000
and
submitted
the
results
to
the
FDA
in
September
2000
as
the
final
portion
of
the
modular
application
for
Pre-Market
Approval
(PMA)
seeking
FDA
authorization
to
market
the
HTA
in
the
United
States.
The
Company
received
FDA
approval
in
April
2001. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | BEI
Medical
Systems
Company
is
focusing
on
developing
and
commercializing
a
new
therapeutic
system,
the
Hydro
ThermAblator,
for
treatment
of
excessing
uterine
bleeding.
For
the
39
weeks
ended
6/30/01,
revenues
fell
88%
to
$155
thousand.
Net
loss
before
extraordinary
item
rose
98%
to
$4.1
million.
Revenues
reflect
the
absence
of
revenues
from
the
Base
Business.
Higher
loss
reflects
negative
gross
margins
and
the
absence
of
a
$1.9
million
gain
from
the
sale
of
assets. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Charles Crocker, 61 Chairman
of Directors | -- | Richard Turner, Ph.D., 54 Pres,
CEO | $327K | Thomas Fry, 56 VP,
Fin. and Admin., Sec. and Treasurer | 217K | John Gormally VP,
Worldwide Sales | -- | Samuel Dickstein, 60 VP,
New Bus. Devel. and Technology | 176K | Dollar amounts are as of 27-Sep-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|